Background
Materials and methods
Data source and search strategy
Study selection and data extraction
Inclusion criteria
Exclusion criteria
Data extraction
Reporting quality assessment
Results
Results of the selection
Serial number | Title | Published date | Developer | Nation | Published journal |
---|---|---|---|---|---|
1 | 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout [21] | 2019 | European League Against Rheumatism. | Europe | Annals of the Rheumatic Diseases |
2 | Management of gout and hyperuricemia: multidisciplinary consensus in Taiwan [22] | 2018 | Astellas, Taiwan | Taiwan, China | Special editorial review |
3 | The British Society for Rheumatology guideline for the management of gout [23] | 2017 | British Society for Rheumatology Standards, Audit and Guidelines Working Group. | UK | Rheumatology |
4 | 1. Diagnosis of acute gout: a clinical practice guideline from the American College of Physicians [24] 2. Management of acute and recurrent gout: A clinical practice guideline from the American College of Physicians [25] | 2017 | American College of Physicians | USA | Annals of Internal Medicine |
5 | [2016 China Gout Clinical Practice Guideline] [26] | 2016 | Chinese Rheumatology Association | China | Zhonghua Nei Ke Za Zhi |
6 | 2016 updated EULAR evidence-based recommendations for the management of gout [27] | 2016 | European League Against Rheumatism | Europe | Clinical and epidemiological research |
7 | Treat-to-target (T2T) recommendations for gout [28] | 2016 | European League Against Rheumatism | Europe | Annals of the Rheumatic Diseases |
8 | Australian and New Zealand recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion in the 3e initiative [29] | 2015 | APLAR, Asia Pacific League of Associations for Rheumatology | Australia and New Zealand | International Journal of Rheumatic Diseases |
9 | 2015 gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative [30] | 2015 | ACR/EULAR | USA and Europe | Annals of the Rheumatic Diseases |
10 | Portuguese recommendations for the diagnosis and management of gout [31] | 2014 | A panel of 78 international rheumatologists in 3e (Evidence, Expertise, Exchange) initiative | Portugal | Prática Clínica |
11 | Clinical practice guidelines for management of gout [32] | 2013 | Spanish Society of Rheumatology | Spain | GuipClinGot |
12 | Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative [33] | 2013 | 3e (Evidence, Expertise, Exchange) initiative/a panel of international rheumatologists | International | Annals of the Rheumatic Diseases |
13 | Italian Society of Rheumatology recommendations for the management of gout [34] | 2013 | Italian Society of Rheumatology | Italy | Reumatismo |
14 | Management of chronic gout in adults [35] | 2012 | University of Texas | USA | National Guideline Clearinghouse |
15 | 1. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia [36] 2. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and anti-inflammatory prophylaxis of acute gouty arthritis [37] | 2012 | American College of Rheumatology | USA | Arthritis Care & Research |
16 | Japanese Guideline for the Management of Hyperuricemia and Gout: second edition [38] | 2011 | Tokyo Women’s Medical University | Japan | Nucleosides, Nucleotides and Nucleic Acids |
17 | Management of initial gout in adults [39] | 2009 | University of Texas | USA | National Guideline Clearinghouse |
Characteristics of the included CPGs
Overall reporting quality
17 | 16 | 15 | 14 | 13 | 12 | 11 | 10 | 9 | 8 | 7 | 6 | 5 | 4 | 3 | 2 | 1 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2009 FNPP | 2011 TWMU | 2012 ACR | 2012 FNPP | 2013 SIR | 2013 3E | 2013 SER | 2014 Portugal | 2015ACR/EULAR | 2015 APLAR | 2016 T2T | 2016 EULAR | 2016 CMA | 2017 ACP | 2017 BSR | 2018 TRA | 2019 ELAR | Total | ||
Basic information | 1a | N | Y | Y | N | Y | Y | Y | Y | N | Y | Y | Y | Y | Y | Y | Y | Y | 14 |
1b | N | N | Y | N | N | N | N | N | Y | N | N | Y | Y | N | N | N | Y | 5 | |
1c | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | N | Y | N | Y | N | N | Y | 13 | |
2 | P | Y | Y | P | Y | Y | N | Y | Y | Y | Y | Y | N | Y | N | Y | Y | 12 | |
3 | N | N | P | N | P | Y | Y | Y | N | N | Y | P | N | Y | N | Y | Y | 7 | |
4 | N | Y | Y | N | Y | Y | N | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | 14 | |
Total | 1 | 4 | 5 | 1 | 4 | 5 | 3 | 5 | 4 | 4 | 4 | 5 | 3 | 5 | 2 | 4 | 6 | 65 | |
Background | 5 | N | N | Y | N | Y | P | Y | N | Y | Y | N | P | Y | Y | Y | Y | P | 9 |
6 | N | Y | Y | Y | N | N | Y | P | N | P | P | N | N | Y | Y | N | P | 6 | |
7a | Y | Y | Y | Y | N | N | N | N | Y | Y | Y | Y | Y | Y | Y | Y | Y | 13 | |
7b | N | Y | N | N | N | N | N | N | N | N | N | Y | N | N | Y | N | N | 3 | |
8a | Y | N | Y | Y | N | N | Y | N | N | N | N | P | Y | Y | Y | Y | P | 8 | |
8b | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | N | P | 0 | |
9a | N | N | Y | N | N | P | Y | P | N | Y | P | Y | P | Y | P | P | Y | 6 | |
9b | N | N | P | P | P | P | Y | P | P | P | Y | Y | Y | Y | P | P | Y | 6 | |
Total | 2 | 3 | 5 | 3 | 1 | 0 | 5 | 0 | 2 | 3 | 2 | 4 | 4 | 6 | 5 | 3 | 3 | 51 | |
Evidence | 10a | N | N | Y | N | Y | Y | P | Y | N | Y | N | P | N | N | Y | Y | N | 7 |
10b | N | N | N | N | Y | N | N | N | N | N | Y | N | P | P | P | N | N | 2 | |
11a | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | N | Y | 16 | |
11b | P | N | N | N | N | Y | P | N | N | N | N | N | P | Y | P | P | N | 2 | |
12 | Y | Y | Y | Y | Y | Y | Y | Y | N | Y | Y | Y | Y | Y | Y | Y | Y | 16 | |
Total | 2 | 2 | 3 | 2 | 4 | 4 | 2 | 3 | 1 | 3 | 3 | 2 | 2 | 3 | 3 | 2 | 2 | 43 | |
Recommendations | 13a | P | Y | Y | P | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | 15 |
13b | N | Y | N | N | N | N | N | N | N | N | N | Y | N | Y | Y | NA | NA | 4 | |
13c | Y | Y | Y | Y | Y | Y | Y | Y | N | Y | Y | Y | Y | Y | Y | Y | Y | 16 | |
14a | N | Y | N | N | N | N | N | N | N | Y | N | N | N | N | N | N | P | 2 | |
14b | N | N | N | N | Y | N | N | N | N | N | N | N | NA | N | Y | N | P | 2 | |
14c | N | N | N | N | Y | N | N | N | N | N | N | N | N | N | P | N | N | 1 | |
15 | N | Y | Y | N | N | Y | Y | Y | Y | Y | Y | Y | P | N | Y | Y | Y | 12 | |
Total | 1 | 5 | 3 | 1 | 4 | 3 | 3 | 3 | 2 | 4 | 3 | 4 | 2 | 3 | 5 | 3 | 3 | 52 | |
Review and quality assurance | 16 | Y | Y | N | N | N | N | N | N | N | N | P | P | N | Y | N | N | P | 3 |
17 | N | N | N | N | N | N | N | N | N | N | N | N | N | N | P | N | N | 0 | |
Total | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 3 | |
Funding and declaration and management of interests | 18a | Y | N | Y | Y | N | Y | Y | N | Y | N | Y | N | N | Y | N | P | Y | 9 |
18b | N | NA | N | N | NA | N | Y | NA | N | NA | N | NA | NA | N | NA | N | N | 1 | |
19a | N | N | Y | N | N | Y | Y | N | Y | N | Y | Y | Y | Y | Y | Y | Y | 11 | |
19b | NA | NA | N | NA | NA | N | N | NA | N | N | N | P | NA | Y | NA | N | Y | 2 | |
Total | 1 | 0 | 2 | 1 | 0 | 2 | 3 | 0 | 2 | 0 | 2 | 1 | 1 | 3 | 1 | 1 | 3 | 23 | |
Other information | 20 | Y | Y | Y | Y | N | Y | N | N | Y | N | Y | Y | N | Y | Y | N | Y | 11 |
21 | N | N | Y | N | N | N | N | N | N | N | N | Y | N | N | Y | N | N | 3 | |
22 | N | N | Y | N | N | Y | N | N | N | P | N | N | N | N | N | N | N | 2 | |
Total | 1 | 1 | 3 | 1 | 0 | 2 | 0 | 0 | 1 | 0 | 1 | 2 | 0 | 1 | 2 | 0 | 1 | 16 | |
9 | 16 | 21 | 9 | 13 | 16 | 16 | 11 | 12 | 14 | 15 | 18 | 12 | 22 | 18 | 13 | 18 | 253 |